International Urology and Nephrology

, Volume 29, Issue 1, pp 25–31 | Cite as

Correlation of nuclear p53 over-expression with clinical and histopathological features of transitional cell bladder cancer

  • Z. Sinik
  • T. Alkibay
  • Ö. Ataoĝlu
  • G. Akyol
  • H. Tokuçoĝlu
  • I. Bozkirli
Article

Abstract

Forty-four pathologic specimens of 39 bladder cancer patients were analyzed immunohistochemically with DO7 monoclonal antibody to detect over-expression of mutant p 53 gene. The findings were interpreted by correlating with patient age, sex, cigarette smoking, number and macroscopic appearance of tumour, histological tumour grade, muscular invasion, vascular invasion, necrosis and urothelial atypia or dysplasia. Mutant p53 gene was over-expressed in 8 (18.2%) specimens. Statistically significant correlation with grdde, vascular invasion, necrosis and patient sex was found with p53 over-expression. Available follow-up data were insufficient to draw a conclusion about the prognostic role of p53 over-expression. Prospective studies with larger number of patients are needed to define the exact place of nuclear p53 over-expression in transitional cell bladder cancer.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Batsakis, J. G., El-Naggar, A. K.: p53: 15 years after discovery.Advanc. Anat. Pathol., 2, 71 (1995).CrossRefGoogle Scholar
  2. 2.
    Esrig, D., Spruck, E. D., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A., Cote, R. J.: p53 nuclear protein accumulation correlates with over-expression and mutations in the p53 gene, tumor grade and stage in bladder cancer.Am. J. Pathol., 143, 1389 (1993).PubMedGoogle Scholar
  3. 3.
    Fradet, Y.: Molecular and immunologic approaches in the management of bladder cancer.Urol. Clin. North Am., 8, 515 (1991).Google Scholar
  4. 4.
    Gardiner, R. A., Walsh, M. D., Allen, V., Rahman, S., Samaratunga, M. L. T. H., Seymour, G. J., Lavin, M. F.: Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression.Br. J. Urol., 73, 526 (1994).PubMedGoogle Scholar
  5. 5.
    Heney, N. M., Nocks, B. N., Daly, J. J., Proud, G. R., Jr., Mewell, J. R. Grissin, P. P., Perrone, T. L., Szyfelbein, W. A.: Ta and T1 bladder cancer: Location, recurrence and progression.Br. J. Urol. 54, 152 (1982).PubMedGoogle Scholar
  6. 6.
    Hollstein, M., Sidransky, D., Vogelstein, B., Harris, C. C.: p53 mutations in human cancer.Science, 253, 49 (1991).PubMedCrossRefGoogle Scholar
  7. 7.
    Lipponen, P. K.: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value.Int. J. Cancer, 53, 365 (1993).PubMedGoogle Scholar
  8. 8.
    Mellon, K., Wilkinson, S., Vickers, J., Robinson, M. C., Shenton, B. K., Neal, D. E. Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder.Br. J. Urol., 73, 522 (1994).PubMedGoogle Scholar
  9. 9.
    Miyao, N., Tsai, Y. C., Lerner, S. P., Spruck, C. H., Gonzales-Zulueta, M., Nichols, P. W., Skinner, D. G., Jones, P. A.: Role of chromosome 9 in human bladder cancer.Cancer Res., 53, 4066 (1994).Google Scholar
  10. 10.
    Ro, J. Y., Staerkel, G. A., Ayala, A. G.: Cytologic and histologic features of superficial bladder cancer.Urol. Clin. North Am 19, 435 (1992).PubMedGoogle Scholar
  11. 11.
    Sarkis, A. S., Dalbagni, G., Cordon-Cardon, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W., Reuter, V. E.: Nuclear over-expression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression.JNCI 85, 53 (1993).PubMedCrossRefGoogle Scholar
  12. 12.
    Sarkis, A. S., Dalbagni, G., Cordon-Cardon, C., Melamed, J., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W., Reuter, V. E.: Association of p53 nuclear over-expression and tumor progression in carcinoma in situ.J. Urol., 152, 388 (1994).PubMedGoogle Scholar
  13. 13.
    Sarosdy, M. F.: Principles of intravesical chemotherapy and immunotherapy.Urol. Clin. North Am., 19, 509 (1992).PubMedGoogle Scholar
  14. 14.
    Sidransky, D., Von, Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., Vogelstein, B.: Identification of p53-gene mutations in bladder cancers and urine samples.Science 252, 706 (1991).PubMedCrossRefGoogle Scholar
  15. 15.
    Spruck, C. H., Rideout, W. M., Olumi, A. F., Ohnseit, P. F., Yang, A. S., Tsai, Y. C., Nichols, P. W., Horn, T., Hermann, G. G., Steven, K., Ross, R. K. Mimi, C. Y., Jones, P. A.: Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usega.Cancer Res., 53, 1162 (1993).PubMedGoogle Scholar
  16. 16.
    Thomas, D. J., Robinson, M. C., Charlton, R., Wilkinson, S., Shenton, B. K., Neal, D. E.: p53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.Br. J. Urol., 73, 533 (1994)PubMedGoogle Scholar
  17. 17.
    Thompson, S. J., Mellon, K., Charlton, R. G., Marsh, C., Robinson, M., Neal, D. E.: p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.Br. J. Urol., 69, 609 (1992).PubMedCrossRefGoogle Scholar
  18. 18.
    Wright, C., Mellon K., Johnston, P., Lane, D. P., Harris, A. L., Horne, C. H. W., Neal, D. E.: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder..Br. J. Cancer, 63, 967 (1991).PubMedGoogle Scholar

Copyright information

© Akadémiai Kiadó 1997

Authors and Affiliations

  • Z. Sinik
    • 1
  • T. Alkibay
    • 1
  • Ö. Ataoĝlu
    • 2
  • G. Akyol
    • 2
  • H. Tokuçoĝlu
    • 1
  • I. Bozkirli
    • 1
  1. 1.Department of UrologyGazi University, School of MedicineAnkaraTurkey
  2. 2.Department of PathologyGazi University, School of MedicineAnkaraTurkey

Personalised recommendations